WO2002065133A2 - Ligands permettant la detection de prions - Google Patents

Ligands permettant la detection de prions Download PDF

Info

Publication number
WO2002065133A2
WO2002065133A2 PCT/EP2002/001451 EP0201451W WO02065133A2 WO 2002065133 A2 WO2002065133 A2 WO 2002065133A2 EP 0201451 W EP0201451 W EP 0201451W WO 02065133 A2 WO02065133 A2 WO 02065133A2
Authority
WO
WIPO (PCT)
Prior art keywords
sample
prpsc
binding
detection
bound
Prior art date
Application number
PCT/EP2002/001451
Other languages
German (de)
English (en)
Other versions
WO2002065133A3 (fr
Inventor
Holger Kiesewetter
Abdulgabar Salama
Original Assignee
Holger Kiesewetter
Abdulgabar Salama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holger Kiesewetter, Abdulgabar Salama filed Critical Holger Kiesewetter
Priority to JP2002564600A priority Critical patent/JP4299541B2/ja
Priority to EP02701272A priority patent/EP1360502B1/fr
Priority to US10/467,612 priority patent/US7208281B2/en
Priority to DE50205750T priority patent/DE50205750D1/de
Publication of WO2002065133A2 publication Critical patent/WO2002065133A2/fr
Publication of WO2002065133A3 publication Critical patent/WO2002065133A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Definitions

  • the present invention relates to the use of ligands for the detection of prions, in particular in the context of a rapid BSE test. Furthermore, substances are disclosed which are suitable for the binding and subsequent detection of prions.
  • Prions are normal cellular proteins (PrPc), which are mainly detected on the surface of neurons.
  • PrPsc normal cellular proteins
  • the transformation of the normal cellular protein into its abnormal isoform (PrPsc) results in a pathogenic form with new properties.
  • the resulting form is not water-soluble and cannot be broken down by proteases.
  • proteases According to the so-called "protein only" hypothesis, the coincidence of pathological and normal prions leads to the fact that the normal molecule changes its conformation and assumes the pathological form. This process leads to the accumulation of these proteins in the brain and finally to encephalopathies, which include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans.
  • Glycosaminoglycans are linear heteropolysaccharides that are based on
  • Prions may also be introduced intracellularly via these molecules.
  • Pentosan poly-b-xylose-2,3-disulfonate; pentosan polysulfate
  • pentosan polysulfate is a polysulfated polyglycoside (molecular weight 4,000 to 12,000 daltons). This molecule appears to inhibit the accumulation of prions. This substance has been shown to be the most prion producing compared to other sulfated GAGS such as heparin, heparan sulfate and chondroitin sulfate inhibited. This inhibition may be due to a direct connection with the prions [B. Caughey and G. Raymond, Journal of Virology, Feb. 1993, p. 643-650; B. Caughey et al, Journal of Virology, Apr.
  • PrP-specific monoclonal and polyclonal antibodies have already been produced which recognize both variants PrPc and PrPsc. With the help of the available monoclonal antibodies, both variants can be differentiated indirectly and thus a disease can be detected.
  • Organisms would be detected. In view of the current incurability of this disease and the proven transferability of the disease from infected animals (e.g. cattle), in which the disease does not yet have to have broken out, however, this would be exactly the same for humans about the ingested food for comprehensive prophylaxis and also of paramount importance for the successful eradication of the disease. The economic damage caused by this disease in the billions should not go unmentioned in this context.
  • the present invention is therefore based on the object of providing a method with which BSE pathogens (PrPsc) can be specifically detected.
  • This method should be easy and quick to use, safe and inexpensive to carry out and enable extremely sensitive detection.
  • the method should be able to be carried out in vitro on samples with a low PrPsc concentration, which can be obtained, for example, from living organisms.
  • the binding principle (ii) is selected from the group consisting of: a glycosaminoglycan, fibronectin or lipoprotein A.
  • BSE pathogens are detected. This means the pathological form of the prion protein (PrPsc).
  • Proteinase K is added to the sample to break down the non-pathological prion protein (PrPc). It is known from the prior art that proteinase K hydrolytically cleaves the non-pathological form, but only a small part of the pathological form of the prion protein. In view of the present invention, however, it is clear to the person skilled in the art that other proteases which satisfy the aforementioned purpose can also be used according to the invention without departing from the scope of the present invention. The methods for hydrolytic cleavage using proteinase K are well known to those skilled in the art. In particular, there are a number of working instructions in laboratory manuals, in which the buffer systems that can be used, the incubation times to be applied and other reaction conditions to be observed are described in detail.
  • the PrPc can be degraded by subjecting a sample to a 30-minute degradation by proteinase K in a 250 ⁇ g / ml proteinase K solution in a conventional Tris / EDTA buffer, pH 7.4, 37 ° C.
  • the non-hydrolytically cleaved prion proteins which according to the invention represent the pathological form PrPsc, are removed from the sample by means of a binding principle.
  • This binding principle is preferably a Glycosaminoglycan, particularly preferably pentosan polyphosphate.
  • Further preferred glycosaminoglycans which can be used according to the invention are heparan sulfate, heparin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratone sulfate or Congo red.
  • An artificially produced sulfated glycosaminoglycan can likewise preferably be used according to the invention.
  • Fibronectin can also preferably be used as a binding principle.
  • Lipoprotein A can also preferably be used as a binding principle.
  • this binding principle is bound to a solid support.
  • Solid carriers are preferably all solid carriers which are known to the person skilled in the field of affinity chromatography.
  • beads are particularly preferably used according to the invention; H. mostly spherical microcarriers made of different materials.
  • solid supports which can preferably be used according to the invention are those column materials which have already found widespread use in affinity chromatography.
  • Microtiter plates coated with the binding principle described above can also preferably be used according to the invention.
  • Europium (Eu) -containing nanobeads from Seradyn, Indianapolis, USA are also particularly preferred. These particles are "sucked up” with Europium chelates, so that the surface remains free for coupling reactions and the Europium chelates do not leak.
  • Europium chelate tris- (naphthyltrifluorobutanedione) -Eu. When these particles are excited with UV light (333 nm maximum), they emit light radiation at 613 nm with a duration of approximately 0.5 milliseconds, which is 10,000 times to 100,000 times longer than the emission duration of most fluorophores.
  • Each particle contains> 30,000 europium atoms, enclosed in tris-naphthyl trifluorobutanedione (a - diketone).
  • quantum yield quantum yield equivalent to approximately 3,000 molecules of fluorescein (one of the most commonly used fluorophores).
  • the phycobiliprotein (probably the most fluorescent compound known) has a quantum gain which corresponds to that of approx. 30 fluorescein molecules. Since a 100 nm particle has a 10 times larger diameter compared to the phycobiliprotein and a 1000 times larger volume mass ratio, these beads have a 100 times higher fluorescence on a molar basis than the phycobiliprotein.
  • the nanoparticles are first irradiated (so-called excitation wavelength - at Europium 340 nm) and after a delay of 400 ⁇ s (in this case) the signals are measured for 400 ⁇ s. This delay prevents the registration of unspecific short-term signals from the matrix.
  • the results are presented in RFU (relative fluorescence units). The measurement runs automatically with a standardized fluorimeter, with which the time-delayed fluorescence can be measured.
  • test system With the help of the test system according to the invention, examinations on samples originating from living organisms, such as blood samples, tissue samples or body fluids such as urine, milk, CSF or saliva, are successfully carried out for the presence of BSE pathogens (PrPsc; pathological form of the prion protein). Studies on soil or plant samples can also be carried out.
  • BSE pathogens PrPsc; pathological form of the prion protein
  • Lysed thrombic starting material is particularly preferably used as the sample.
  • a blood sample is brought to coagulation and the thrombic material formed is separated off.
  • the thrombic material is broken down by hydrolysis with a proteinase, and the resulting sample is used directly in the test.
  • the BSE pathogen bound to the binding principle is preferably detected using specific antibody tests. These tests and detection methods are also well known to the person skilled in the art. To be mentioned as an example here ELISA and RIA procedures as well as agglutination tests and flow cytometry.
  • a reinforcement system such as an enzyme coupled to the first or second antibody can be used particularly preferably according to the invention.
  • a particularly preferred system according to the invention for the detection of the PrPSc bound to the binding principle comprises antibodies covalently bound to nanoparticles with a diameter of 10-100 nm.
  • the nanoparticles contain europium.
  • the antibodies of the preceding paragraph are not covalently bound to the nanobead via the biotin / streptavidin system, which is well known to the person skilled in the art, the antibodies preferably being biotinylated.
  • the carrier is present for the detection, in particular in the form of an Eu marking (EU nanobeads), and after depletion from the sample by binding to a second binding principle, in particular a specific anti - PrPsc antibody the corresponding label is detected by appropriate detection, in particular the time-delayed fluorescence.
  • Toyopearl HW55 (commercially available cross-linked polyacrylate gel from Toyo Soda Manufacturing Co. Ltd., with a particle size of 50-100 ⁇ m) was used as the carrier.
  • Test samples containing prions are treated with proteinase K using conventional methods to eliminate the normal prion proteins PrPc.
  • the sample is adjusted to a concentration of 50 ⁇ g / ml Proteinase K (Boehringer) and incubated for 1 hour at 37 ° C.
  • concentration of 50 ⁇ g / ml Proteinase K Boehringer
  • Proteinase K (Sigma, Cat No. 82456) are pipetted into 1 ml of sample.
  • the supernatant is mixed with pentosan polyphosphate coated beads from Example 1. It has been shown here that the presence of ImM zinc promotes binding.
  • the beads are sedimented by centrifugation in a Hettich table centrifuge and separated from the test sample.
  • the beads labeled with the second antibody were detected using flow cytometry.
  • antibodies For the covalent binding of antibodies to nanobeads (FluoroMax TM Fluorescent microparticles, Seradyn, Indianapolis, USA), these are treated with carbodumide and hydroxysuccinimide in order to ensure a secure and firm bond between the carboxyl groups on the particle surface and the protein molecules (antibodies). In this way, the antibodies remain stably bound to the nanoparticles (longer durability of the conjugate). The antibodies cannot be separated from the beads in the subsequent treatments (different reaction buffers).
  • Europium nanoparticles were obtained from Seradyn, Indianapolis, USA. These particles are "sucked up” with Europium chelates, so that the surface remains free for coupling reactions and the Europium chelates do not leak.
  • Europium chelate tris- (naphthyltrifluorobutanedione) -Eu. When these particles are excited with UV light (333 nm maximum), they emit light radiation at 613 nm with a duration of approximately 0.5 milliseconds, which is 10,000 times to 100,000 times longer than the emission duration of most fluorophores. This extremely long emission period and the long one
  • the nanoparticles are first irradiated (so-called excitation wavelength - at Europium 340 nm) and after a delay of 400 ⁇ s (in this case) the signals are measured for 400 ⁇ s. This delay prevents the registration of unspecific short-duration signals from the matrix.
  • the results are presented in RFU (relative fluorescence units). The measurement runs automatically with a standardized fluorimeter, with which the time-delayed fluorescence can be measured. This system is described, inter alia, by Ci, Y., et al, J. Immun. Meth., 179, 233-241, 1995 and Souka et al. Clin. Chem., 47: 3, 561-568.
  • Biotin is used in the so-called two-step techniques in connection with conjugated or immobilized strept (avidin).
  • the binding of the biotin to the strept (avidin) is very fast and stable.
  • Various techniques for biotinylating antibodies have been described. There are also kits from several companies with the appropriate protocol.
  • the biotin is conjugated by the primary amines of the proteins (e.g. lysine) and so 3 to 6 molecules of biotin are bound per protein molecule.
  • the sulfo-NHS-LC biotin Pierce
  • the separation of the non-conjugated biotin from the antibody can be carried out using centrifuge microconcentrators Nanosep TM (Pall).
  • the stage of biotinylation is determined by the so-called HABA reaction (HABA-2- (4'hydroxyazobenzene) -benzoic acid) with excess avidin determined photometrically.
  • the coating of the nanoparticles with streptavidin is carried out according to Härze et al. , Clin. Chem., 47: 3; 561-568 (2001). After pre-washing the beads with PBS, pH 7.0 with Nanosep TM centrifuge microconcentrators, they are resuspended in the same buffer with an ultrasound probe. The carboxyl groups are then activated with 10 mM N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide (EDAC), (Pierce) and N-hydroxysulfosuccinimide (NHS), (Sigma) for 30 minutes.
  • EDAC N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide
  • NHS N-hydroxysulfosuccinimide
  • the (nano) beads can be separated from the sample by centrifugation and / or by using so-called centrifuge concentrators (microfilters). Depending on the bond strength between fibronectin and PrPsc, the beads-PrPsc complexes can be washed in order to achieve the highest possible separation of the two PrP forms.
  • Fibronectin is coupled with nanobeads (Europium nanobeads).
  • PrPSc PrP
  • PrPC normal form
  • the fibronectin nanobeads are then separated from the sample by centrifugation and resuspended in a reaction buffer.
  • the resuspended fibronectin nanobeads are incubated on a microtiter plate coated with monoclonal antibodies (against PrP) (formation of the complex MoAk-PrPSc-fibronectin nanobeads).
  • Antigen-MP-FN Incubation • Dilute the MP-FN 1: 742 in PBS-Tween20 2% (PBS Pierce Cat. No. 28374; Tween20 2%). • Pipette 50 ⁇ l of sample treated with 50 ⁇ l of proteinase K and 50 ⁇ l of diluted MP-FN into Eppendor tubes and incubate for 2 hours at room temperature with constant mixing.
  • Fibronectin is coupled with beads (polystyrene beads): Proteinase K-treated and untreated samples are incubated with fibronectin nanobeads
  • the sample is then incubated with the fibronectin beads.
  • the fibronectin beads are then washed and resuspended in a reaction buffer.
  • the resuspended beads are incubated with a monoclonal fluorescence-labeled antibody (against PrP).
  • the fluorescence signals are measured in a flow cytometer.
  • EXAMPLE 10 Binding of PrPSc in microtiter plates coated with fibronectin. 1. The microtiter plate is coated with fibronectin (coated).
  • PrPSc pathological form of PrP adheres to the fibronectin and the normal form (PrPC) does not remain dissolved in the reaction mixture.
  • the europium nanobeads coupled with monoclonal antibodies are pipetted into the microtiter plate and incubated.
  • Example 10 Lipoprotein A was used instead of fibronectin. Apolipoprotein A can also be used.
  • Example 11 Lipoprotein A was used instead of fibronectin. Apolipoprotein A can also be used).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de supports de ligands spécifiques pour détecter des prions. Cette invention concerne également des substances capables de se lier à des prions et ainsi de mettre leur présence en évidence.
PCT/EP2002/001451 2001-02-13 2002-02-12 Ligands permettant la detection de prions WO2002065133A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002564600A JP4299541B2 (ja) 2001-02-13 2002-02-12 プリオンを検出するためのリガンド
EP02701272A EP1360502B1 (fr) 2001-02-13 2002-02-12 Ligands permettant la detection de prions
US10/467,612 US7208281B2 (en) 2001-02-13 2002-02-12 Ligands used for detecting prions
DE50205750T DE50205750D1 (de) 2001-02-13 2002-02-12 Liganden für den nachweis von prionen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10107083A DE10107083C2 (de) 2001-02-13 2001-02-13 Pentosan Polysulfat als Ligand zum Nachweis von Prionen
DE10107083.7 2001-02-13

Publications (2)

Publication Number Publication Date
WO2002065133A2 true WO2002065133A2 (fr) 2002-08-22
WO2002065133A3 WO2002065133A3 (fr) 2003-01-03

Family

ID=7674166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001451 WO2002065133A2 (fr) 2001-02-13 2002-02-12 Ligands permettant la detection de prions

Country Status (6)

Country Link
US (1) US7208281B2 (fr)
EP (1) EP1360502B1 (fr)
JP (1) JP4299541B2 (fr)
AT (1) ATE317126T1 (fr)
DE (2) DE10107083C2 (fr)
WO (1) WO2002065133A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111652A1 (fr) * 2003-06-19 2004-12-23 Applied Research Systems Ars Holding N.V. Utilisation d'agents modulateurs de la conversion de prions
FR2865279A1 (fr) * 2004-01-20 2005-07-22 Biomerieux Sa Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique
FR2865280A1 (fr) * 2004-01-20 2005-07-22 Biomerieux Sa Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique
EP1615992A2 (fr) * 2003-04-04 2006-01-18 American Red Cross Materiaux de liaison a la proteine prion et procedes d'utilisation
EP1616036A2 (fr) * 2003-04-14 2006-01-18 American National Red Cross Procede d'identification de ligands specifiques pour des isoformes structurales de proteines
EP1643252A2 (fr) * 2004-09-30 2006-04-05 Ortho-Clinical Diagnostics, Inc. Peptides pour la discrimination des prions
EP2128618A1 (fr) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. Procédé pour le suivi de la présence d'agents pathogènes dans des fluides biologiques par des matériaux nanostructurés
US7807386B2 (en) * 2004-09-30 2010-10-05 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
US8158441B2 (en) 2005-07-21 2012-04-17 Biomerieux S.A. Method for detecting aggregate-forming circulating protein forms using an agent for aggregating said forms and an agent for capturing formed aggregates

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658374B2 (en) 2002-02-28 2014-02-25 Microsens Biphage Limited Binding of aggregated forms of proteins
MXPA04008275A (es) * 2002-02-28 2005-04-25 Microsens Biophage Ltd Enlace de formas patologicas de proteinas de prion.
FR2849205B1 (fr) * 2002-12-20 2005-02-11 Afssa Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification
EP1445615A1 (fr) * 2003-02-10 2004-08-11 Ortho-Clinical Diagnostics, Inc. Procede pour discrimination des prions infectieux et non infectieux
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
EP1677114A1 (fr) * 2004-11-15 2006-07-05 Roche Diagnostics GmbH Analyses de prion à haut débit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19730132A1 (de) * 1997-07-14 1999-02-11 Fraunhofer Ges Forschung Verfahren zum Nachweis von Prionen sowie eine Vorrichtung hierzu
WO2000029850A1 (fr) * 1998-11-17 2000-05-25 Wallac Oy Immuno-essai de recherche d'encephalopathies spongiformes transmissibles chez les bovins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033907A (en) * 1995-09-29 2000-03-07 Indiana University Foundation Enhanced virus-mediated DNA transfer
DE69818388T2 (de) * 1997-02-06 2004-07-01 Enfer Technology Ltd. Immunoassay für spongiforme encephalopathien
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
GB9902659D0 (en) * 1999-02-05 1999-03-31 Microbiological Res Authority Assay with reduced background

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19730132A1 (de) * 1997-07-14 1999-02-11 Fraunhofer Ges Forschung Verfahren zum Nachweis von Prionen sowie eine Vorrichtung hierzu
WO2000029850A1 (fr) * 1998-11-17 2000-05-25 Wallac Oy Immuno-essai de recherche d'encephalopathies spongiformes transmissibles chez les bovins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIMACOMBE DEBBIE B ET AL: "Characterization and polyanion-binding properties of purified recombinant prion protein." BIOCHEMICAL JOURNAL, Bd. 342, Nr. 3, Seiten 605-613, XP002214909 ISSN: 0264-6021 *
CAUGHEY B ET AL: "BINDING OF THE PROTEASE-SENSITIVE FORM OF PRION PROTEIN PRP TO SULFATED GLYCOSAMINOGLYCAN AND CONGO RED" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, Bd. 68, Nr. 4, 1. April 1994 (1994-04-01), Seiten 2135-2141, XP002056076 ISSN: 0022-538X *
See also references of EP1360502A2 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842707B (zh) * 2003-04-04 2012-06-27 病毒去除和诊断科技公司 朊病毒蛋白结合材料及其使用方法
EP1615992A2 (fr) * 2003-04-04 2006-01-18 American Red Cross Materiaux de liaison a la proteine prion et procedes d'utilisation
JP4783727B2 (ja) * 2003-04-04 2011-09-28 パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレーテッド プリオンタンパク質結合物質と使用法
EP1615992A4 (fr) * 2003-04-04 2007-11-07 Pathogen Removal And Diagnosti Materiaux de liaison a la proteine prion et procedes d'utilisation
AU2004227389B2 (en) * 2003-04-04 2010-09-16 North Carolina State University Prion protein binding materials and methods of use
JP2006522344A (ja) * 2003-04-04 2006-09-28 アメリカン レッド クロス プリオンタンパク質結合物質と使用法
EP1616036A4 (fr) * 2003-04-14 2007-03-21 Pathogen Removal And Diagnosti Procede d'identification de ligands specifiques pour des isoformes structurales de proteines
EP1616036A2 (fr) * 2003-04-14 2006-01-18 American National Red Cross Procede d'identification de ligands specifiques pour des isoformes structurales de proteines
WO2004111652A1 (fr) * 2003-06-19 2004-12-23 Applied Research Systems Ars Holding N.V. Utilisation d'agents modulateurs de la conversion de prions
NO338179B1 (no) * 2003-06-19 2016-08-01 Merck Serono Sa Anvendelse av prionkonverteringsmodulerende midler
AU2004248302B2 (en) * 2003-06-19 2009-07-30 Merck Serono Sa Use of prion conversion modulating agents
US7598046B2 (en) 2003-06-19 2009-10-06 Laboratories Serono Sa Use of prion conversion modulating agents
FR2865279A1 (fr) * 2004-01-20 2005-07-22 Biomerieux Sa Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique
WO2005080590A1 (fr) * 2004-01-20 2005-09-01 Biomerieux PROCEDE DE DETECTION DE LA PrP UTILISANT UNE MOLECULE AYANT AU MOINS UNE CHARGE POSITIVE ET/OU AU MOINS UNE LIAISON OSIDIQUE ET UN LIGAND AUTRE QU’UN LIGAND PROTEIQUE
US7566530B2 (en) 2004-01-20 2009-07-28 Biomerieux Method for detecting PrP using at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand
FR2865280A1 (fr) * 2004-01-20 2005-07-22 Biomerieux Sa Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique
EP1643252A2 (fr) * 2004-09-30 2006-04-05 Ortho-Clinical Diagnostics, Inc. Peptides pour la discrimination des prions
US7807386B2 (en) * 2004-09-30 2010-10-05 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
EP2085404A1 (fr) * 2004-09-30 2009-08-05 Ortho-Clinical Diagnostics, Inc. Peptides pour la discrimination des prions
EP1643252A3 (fr) * 2004-09-30 2006-05-31 Ortho-Clinical Diagnostics, Inc. Peptides pour la discrimination des prions
AU2005209592B2 (en) * 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
JP2006105988A (ja) * 2004-09-30 2006-04-20 Ortho-Clinical Diagnostics Inc プリオンの区別のためのペプチド
US8158441B2 (en) 2005-07-21 2012-04-17 Biomerieux S.A. Method for detecting aggregate-forming circulating protein forms using an agent for aggregating said forms and an agent for capturing formed aggregates
EP2128618A1 (fr) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. Procédé pour le suivi de la présence d'agents pathogènes dans des fluides biologiques par des matériaux nanostructurés

Also Published As

Publication number Publication date
WO2002065133A3 (fr) 2003-01-03
DE50205750D1 (de) 2006-04-13
EP1360502A2 (fr) 2003-11-12
EP1360502B1 (fr) 2006-02-01
US7208281B2 (en) 2007-04-24
JP4299541B2 (ja) 2009-07-22
DE10107083A1 (de) 2002-08-29
DE10107083C2 (de) 2003-02-20
US20040096902A1 (en) 2004-05-20
JP2004518966A (ja) 2004-06-24
ATE317126T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
EP1360502B1 (fr) Ligands permettant la detection de prions
DE60121958T2 (de) Frühdiagnose von konformationellen erkrankungen
EP3014279A2 (fr) Procédé de détection d'aggrégats de protéines à l'aide de la technique surface-fida
EP2794655A2 (fr) Procédé de quantification sélective d'agrégats de bêta-amyloïde
EP1304336B1 (fr) Anticorps pour la détection spécifique de prions pathogènes d'origine humaine et procédés de détection les utilisants
AU2002226643B2 (en) Test for transmissible spongiform encephalopathies
EP1902317B1 (fr) Procede de determination selective de depots proteiques pathologiques
CA2452946C (fr) Methode de detection des symptomes et de diagnostic d'encephalopathies spongiformes transmissibles
AU2002226643A1 (en) Test for transmissible spongiform encephalopathies
JP7383249B2 (ja) β－１，３－１，６－グルカンの測定方法
EP1329720A2 (fr) Procédé de détection des protéines prions par la spectrométrie de masse
DE102006010647A1 (de) Test zum Nachweis von pathologischen Prionen
WO2019101250A1 (fr) Procédé de quantification d'agrégats de protéines dans un échantillon, dans le cas d'une maladie liée à un repliement anormal de protéines
DE10361243B4 (de) Untersuchungsverfahren zur Phagozytose
US20050147989A1 (en) Screening assay for aggregations
DE10354207B3 (de) Verfahren zum Nachweis von pathologisch veränderten Prion-Proteinen (PrPSc) und Kit zur Durchführung des Verfahrens
US20050282238A1 (en) High-sensitivity chemiluminescent ELISA prion detection method
EP1321771A1 (fr) Procédé de determination qualitative et/ou quantitative des aggrégats
DE4343480A1 (de) Acylierte Proteinaggregate und deren Verwendung zur Signalsteigerung in einem Immunoassay zum Nachweis von Antikörpern
EP1262777A2 (fr) Détection des pathogènes et substances cellulaires induits par les pathogènes in vivo
JP2005516198A (ja) ｉｎｖｉｖｏおよびｉｎｖｉｔｒｏでの方法に関する補体媒介性アッセイ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002701272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 751/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002564600

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002701272

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10467612

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002701272

Country of ref document: EP